Palladium Wren

Microdosing ibogaine · evidence as of 2026

Evidence Review

A synthesis of what the literature can—and cannot—say about ibogaine microdosing, cardiac risk, and the uncertainty behind reassuring dose claims.

Microdosing has little direct clinical evidence; established cardiac concerns do not disappear because the intended amount is smaller.

Abstract close view suggesting the careful interpretation of ibogaine microdosing evidence

01 / scope

The evidence boundary is the first finding.

Published work on ibogaine largely concerns acute, higher-dose exposure, often in treatment-seeking populations or laboratory systems. It should not be automatically transferred to repeated low-dose use.

What is known

Mechanism matters before outcome claims.

Ibogaine and its metabolite noribogaine have pharmacology that can affect cardiac electrical signaling. In particular, laboratory work has raised concern about blockade of the hERG potassium channel, a pathway associated with delayed cardiac repolarization and QT prolongation.

That concern is not an abstract technicality: the FDA’s discussion of QT-related abnormal rhythms illustrates why changes in repolarization are treated seriously in drug safety assessment. For a broader orientation to the compound and its history, the ibogaine overview is useful context, not a safety endorsement.

“Absence of a dedicated microdosing trial is not evidence that the practice is harmless.”
Interpretive limit

02 / laboratory signals

Animal and in vitro findings are signals, not assurances.

Preclinical research helps identify plausible hazards. It cannot supply a real-world safety threshold for a person taking repeated small amounts outside a controlled study.

A key channel

hERG

A potassium-channel target central to many evaluations of drug-induced QT prolongation.

Interpretation

Concentration is not the same thing as a dose.

Cell and animal studies examine exposure under conditions that may not map cleanly onto a person’s blood levels, tissue levels, genetic differences, liver metabolism, or co-exposures. The hERG signal is therefore a reason for caution, not a calculator for self-directed dosing.

The NCBI overview of drug-induced QT prolongation describes why a drug’s effect can be amplified by clinical variables such as electrolyte abnormalities and interacting medicines.

Evidence quality

Useful for hazard identification.

Laboratory data can support biological plausibility. They do not establish how often an outcome occurs in microdosing, who is most vulnerable, or whether a proposed regimen changes risk over time.

Detailed visual texture accompanying discussion of ibogaine dose modeling and uncertainty

03 / pharmacokinetic models

The ~0.87 mg/kg figure is a modeling caveat, not a safe-dose finding.

Some toxicokinetic and modeling discussions have produced an approximate ~0.87 mg/kg figure under particular assumptions about exposure and cardiac-channel effects. It is sometimes repeated as though it defines a personal “safe” microdose. It does not.

A modeled threshold depends on its inputs: concentrations, model structure, assumptions about metabolite behavior, and the relationship between a laboratory signal and clinical arrhythmia. It does not account fully for product variability, cumulative patterns, illness, individual metabolism, or combinations with other substances.

  • Model output: a conditional estimate produced from selected assumptions.
  • Clinical safety threshold: not established for ibogaine microdosing.
  • Practical implication: a numerical figure should not be used to justify unsupervised exposure.

People comparing options often encounter discussion of ibogaine treatment costs alongside dose claims, but price or format cannot validate a dose as medically safe. Location also does not resolve the evidence gap; the practical differences described in ibogaine treatment location information should not be confused with proof of cardiac safety.

04 / clinical harms

Case reports cannot quantify risk, but they define the stakes.

Reports of QT prolongation, torsades de pointes, and deaths after ibogaine exposure are not microdosing trials. They are nevertheless relevant warning signals for a substance with plausible proarrhythmic effects.

What the reports support

Serious rhythm events have been described after ibogaine exposure.

Case material cannot determine an event rate or prove that ibogaine alone caused every outcome. Many reports involve incomplete histories, varying product identity, other substances, medical conditions, or uncertain timelines. Those limitations matter.

But the reports also make it inappropriate to treat smaller intended doses as free from cardiac concern. Torsades de pointes is a potentially life-threatening ventricular rhythm associated with QT prolongation; the clinical description of torsades de pointes explains why the pattern is regarded as an emergency rather than a minor side effect.

05 / gaps and next questions

What a useful evidence base would need to answer.

As of 2026, direct clinical evidence for ibogaine microdosing remains insufficient to establish cardiac safety, benefit, dose-response relationships, or long-term outcomes.

Research needs

Better questions are more important than confident conclusions.

Meaningful research would define the product and dose, measure ibogaine and noribogaine exposure, document co-medications and health factors, use appropriate cardiac monitoring, and follow participants long enough to identify delayed or cumulative harms.

It would also need to separate anecdote from outcome measurement. The basic framing of ibogaine therapy can help distinguish supervised-treatment language from microdosing claims, while documented long-term side-effect concerns underline why short-term impressions are not enough.

“A report of feeling well is not a cardiac safety endpoint.”
Evidence standard

06 / common questions

A careful reading of the uncertainty.

The practical question is not whether every small exposure causes harm. It is whether present evidence can reliably identify a harmless pattern. It cannot.

Does a small amount remove the cardiac concern?

No. A smaller amount may change exposure, but it does not establish safety. Dose, metabolism, other medicines, electrolyte status, and unrecognized heart vulnerability can all matter.

What does the 0.87 mg/kg figure mean?

It is a modeling output discussed in toxicokinetic work, not a clinically proven safe dose or a recommendation for unsupervised use.

What evidence is still missing?

There are no adequate controlled clinical studies establishing the cardiac safety, longer-term effects, or interaction profile of repeated ibogaine microdosing. The risk primer’s practical overview places that absence beside the concerns already known from broader ibogaine exposure.

Why do case reports matter if they cannot prove cause?

Case reports cannot calculate frequency or prove causation on their own, but they can identify serious patterns that deserve caution and further study. For a more concrete way to organize unresolved concerns, see the microdose safety considerations.